当前位置:首页 > 抑制剂
产品编号:  AD.E0003-1g 中文名称:  西妥昔单抗
中文别名:   英文名称:  CETUXIMAB
英文别名:   品牌: ANDY
规格型号:  1g CAS号:  205923-56-4
分子式:  C107H179N35O36S7 分子量: 2756.23
外观与性状:   储存条件:
纯度:  99.0%
标准价:  询价篮 优惠价:  暂无
数量:  

单位:  
库存与货期:  订货

加入购物车   加入询价篮   收藏

商品信息

Cetuximab (C225)是一种单克隆抗体,能够抑制 EGFRSPR 方法测得 Cetuximab  EGFR  Kd 值为 0.201 nMCetuximab 具有高效的抗肿瘤作用。


生物活性

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity[1].

IC50 & Target

 

 

Soluble EGFR

0.201 nM (Kd)

EGFR

0.147 nM (Kd, Fixed A431 cells)

体外研究
(In Vitro)

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a Kd of 0.147 nM for EGFR in fixed A431 cells by ELISA[1]. Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G0/G1 arrest, induces apoptosis, and reduces Rb, p27KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells[3].

体内研究
(In Vivo)

Cetuximab (1?mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts[2].

Clinical Trial

NCT Number

Sponsor

Condition

Start Date

Phase

NCT04065555

Presage Biosciences|Takeda

Head and Neck Cancer

October 7, 2020

Early Phase 1

NCT00875849

Centre Antoine Lacassagne

Head and Neck Cancer

March 2008

Phase 2

NCT02555644

Eli Lilly and Company

Head and Neck Neoplasms

February 24, 2016

Phase 1

分子量

145543.35

CAS

205923-56-4

中文名称

西妥昔单抗

SMILES

[Cetuximab]

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Goldstein NI, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1(11):1311-8.

[2]. Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.

[3]. Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40.


COA

批号:
 

 

 
                                                                                                             
 

 

 首 页 | 公司简介 | 客户服务 | 联系我们 | 常见问题 | 投诉与建议

         江西安迪科技有限公司     版权所有
Copyright ANPEL Laboratory Technologies (Shanghai) Inc.   All Rights Reserved (R)

 联系电话:86-21-54890099 传真:86-21-54248311

     
               
  沪ICP备 08012727 ><!-- Inject Script Filtered -->



版权所有:江西安迪科技有限公司 赣ICP备 2020014206号